4.8 Article

Bacteria and bacterial derivatives as drug carriers for cancer therapy

期刊

JOURNAL OF CONTROLLED RELEASE
卷 326, 期 -, 页码 396-407

出版社

ELSEVIER
DOI: 10.1016/j.jconrel.2020.07.009

关键词

Bacteria; Bacteria-derived membrane vesicles; Drug delivery; Cancer; Immunotherapy

资金

  1. National Natural Science Foundation of China [21875135]
  2. Recruitment Program of Global Youth Experts of China [D1410022]
  3. Shanghai Municipal Education Commission-Gaofeng Clinical Medicine Grant Support [20181704]
  4. Innovative Research Team of High-Level Local Universities in Shanghai [SSMU-ZLCX20180701]
  5. Youth Science and Technology Talents Yang Fan Plan of Shanghai [19YF1427800]

向作者/读者索取更多资源

The application of bacteria and bacteria-derived membrane vesicles (MVs) has promising potential to make a great impact on the development of controllable targeted drug delivery for combatting cancer. Comparing to most other traditional drug delivery systems, bacteria and their MVs have unique capabilities as drug carriers for cancer treatment. They can overcome physical barriers to target and accumulate in tumor tissues and initiate antitumor immune responses. Furtherly, they are able to be modified both genetically and chemically, to produce and transport anticancer agents into tumor tissues with improved safety and efficacy of cancer treatment but decreased cytotoxic effects to normal cells. In this review, we present some examples of tumor-targeting bacteria and bacteria-derived MVs for the delivery of anticancer drugs, including chemo-therapeutic, radio-therapeutic, photothermal-therapeutic, and immuno-therapeutic agents. We also discuss the advantages as well as the limitations of these tumor-targeting bacteria and their MVs used as platforms for controlled delivery of anticancer therapeutic agents, and further highlight their great potential on clinical translation.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.8
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据